Literature DB >> 27888377

Correlation between status of epidermal growth factor receptor mutation and distant metastases of lung adenocarcinoma upon initial diagnosis based on 1063 patients in China.

Hongwei Li1,2, Jianzhong Cao3, Xiaqin Zhang3, Xing Song3, Weili Wang3, Sufang Jia3, Zhengran Li3, Haixia Jia3, Xing Cao3, Wei Zhou3, Jianhong Lian4, Songye Han5, Weihua Yang5, Yanfen Xi6, Shenming Lian3, Haoxing Jing7,8.   

Abstract

The study aimed to explore the correlations between status of epidermal growth factor receptor (EGFR) mutations and distant metastases. A total of 1063 patients with lung adenocarcinoma indentified with status of EGFR mutations from August 2010 to May 2015 at Shanxi Cancer Hospital were enrolled. 456 patients were confirmed with EGFR mutations. The associations among EGFR mutations, clinical factors, and distant metastases at initial diagnosis were evaluated. Patients harboring EGFR mutation were more likely to be female (P < 0.001), with no smoking history (P < 0.001), brain metastases (P = 0.029), and higher ECOG performance scores (P = 0.025). The correlation between EGFR mutation status and distant metastases showed statistical significance both in univariate (P = 0.022) and in multivariate analysis (OR 1.573, 95 % CI 1.202-2.059, P = 0.001) especially in brain metastases (OR 1.675, 95 % CI 1.132-2.479, P = 0.010) and lung metastases (OR 1.571, 59 % CI 1.101-2.243 P = 0.013). Furthermore, the 19del mutations showed associations with brain metastases (OR 1.586, 95 % CI 1.028-2.447, P = 0.037), and lung metastases (OR 1.587, 95 % CI 1.065-2.346, P = 0.023). The exon 21 point mutations showed statistically significant differences in liver metastases (OR 1.987, 95 % CI 1.094-3.067, P = 0.024). In conclusion, the EGFR mutations in lung adenocarcinoma patients were independently correlated with distant metastases. Subgroup analyses showed that patients harboring 19del mutations presented different distant metastases compared with those harboring 21 point mutaions.

Entities:  

Keywords:  Distant metastases; EGFR mutation; Lung adenocarcinoma

Mesh:

Substances:

Year:  2016        PMID: 27888377     DOI: 10.1007/s10585-016-9822-x

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  38 in total

1.  Prognosis in advanced lung cancer--A prospective study examining key clinicopathological factors.

Authors:  Claribel P Simmons; Filippos Koinis; Marie T Fallon; Kenneth C Fearon; Jo Bowden; Tora S Solheim; Bjorn Henning Gronberg; Donald C McMillan; Ioannis Gioulbasanis; Barry J Laird
Journal:  Lung Cancer       Date:  2015-03-28       Impact factor: 5.705

2.  Five-year lung cancer screening experience: CT appearance, growth rate, location, and histologic features of 61 lung cancers.

Authors:  Rebecca M Lindell; Thomas E Hartman; Stephen J Swensen; James R Jett; David E Midthun; Henry D Tazelaar; Jayawant N Mandrekar
Journal:  Radiology       Date:  2007-02       Impact factor: 11.105

3.  4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index.

Authors:  François Blanchon; Michel Grivaux; Bernard Asselain; François-Xavier Lebas; Jean-Pierre Orlando; Jacques Piquet; Mahmoud Zureik
Journal:  Lancet Oncol       Date:  2006-10       Impact factor: 41.316

4.  Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS).

Authors:  C R Newton; A Graham; L E Heptinstall; S J Powell; C Summers; N Kalsheker; J C Smith; A F Markham
Journal:  Nucleic Acids Res       Date:  1989-04-11       Impact factor: 16.971

5.  EGFR mutation and brain metastasis in pulmonary adenocarcinomas.

Authors:  Dong-Yeop Shin; Im Il Na; Cheol Hyeon Kim; Sunhoo Park; HeeJong Baek; Sung Hyun Yang
Journal:  J Thorac Oncol       Date:  2014-02       Impact factor: 15.609

6.  HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors.

Authors:  Menghong Sun; Carmen Behrens; Lei Feng; Natalie Ozburn; Ximing Tang; Guosheng Yin; Ritsuko Komaki; Marileila Varella-Garcia; Waun Ki Hong; Kenneth D Aldape; Ignacio I Wistuba
Journal:  Clin Cancer Res       Date:  2009-07-21       Impact factor: 12.531

7.  Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer.

Authors:  C-H Gow; Y-L Chang; Y-C Hsu; M-F Tsai; C-T Wu; C-J Yu; C-H Yang; Y-C Lee; P-C Yang; J-Y Shih
Journal:  Ann Oncol       Date:  2008-12-16       Impact factor: 32.976

8.  Prophylactic cranial irradiation in extensive small-cell lung cancer.

Authors:  Ben Slotman; Corinne Faivre-Finn; Gijs Kramer; Elaine Rankin; Michael Snee; Matthew Hatton; Pieter Postmus; Laurence Collette; Elena Musat; Suresh Senan
Journal:  N Engl J Med       Date:  2007-08-16       Impact factor: 91.245

9.  The incidence of EGFR-activating mutations in bone metastases of lung adenocarcinoma.

Authors:  Paweł Krawczyk; Marcin Nicoś; Rodryg Ramlau; Tomasz Powrózek; Kamila Wojas-Krawczyk; Sylwia Sura; Bożena Jarosz; Justyna Szumiło; Edward Warda; Tomasz Mazurkiewicz; Marek Sawicki; Janusz Milanowski
Journal:  Pathol Oncol Res       Date:  2013-07-14       Impact factor: 3.201

10.  EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital.

Authors:  Yoon-La Choi; Jong-Mu Sun; Juhee Cho; Sanjay Rampal; Joungho Han; Bhash Parasuraman; Eliseo Guallar; Genehee Lee; Jeeyun Lee; Young Mog Shim
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

View more
  7 in total

Review 1.  The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era.

Authors:  Alessia Spagnuolo; Matteo Muto; Fabio Monaco; Giuseppe Colantuoni; Cesare Gridelli
Journal:  Transl Lung Cancer Res       Date:  2019-12

2.  Correlation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancer.

Authors:  Lina Li; Shuimei Luo; Heng Lin; Haitao Yang; Huijuan Chen; Ziyuan Liao; Wanzun Lin; Weili Zheng; Xianhe Xie
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

3.  EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases.

Authors:  Kai Dong; Wenhua Liang; Shen Zhao; Minzhang Guo; Qihua He; Caichen Li; Haiqing Song; Jianxing He; Xiaojun Xia
Journal:  Transl Lung Cancer Res       Date:  2019-06

4.  Inferior outcome of bone metastasis in non-small-cell-lung-cancer patients treated with epidermal growth factor receptor inhibitors.

Authors:  Yue-Yun Chen; Pei-Pei Wang; Yang- Fu; Qing- Li; Jiang-Fang Tian; Ting- Liu; Zhen Lin; Zhen-Yu Ding
Journal:  J Bone Oncol       Date:  2021-05-04       Impact factor: 4.072

5.  EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients.

Authors:  Heather Scharpenseel; Annkathrin Hanssen; Sonja Loges; Malte Mohme; Christian Bernreuther; Sven Peine; Katrin Lamszus; Yvonne Goy; Cordula Petersen; Manfred Westphal; Markus Glatzel; Sabine Riethdorf; Klaus Pantel; Harriet Wikman
Journal:  Sci Rep       Date:  2019-05-15       Impact factor: 4.379

Review 6.  [Association between EGFR, ALK and KRAS Gene Status and Synchronous Distant 
Organ Metastasis in Non-small Cell Lung Cancer].

Authors:  Ge Gao; LiLi Deng
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-07-20

7.  Next-generation sequencing assisted diagnosis of cervical metastasis in EGFR-mutated lung adenocarcinoma: A case report.

Authors:  Li Xu; Kang Li; Xiaoyan Chen; Bolin Chen; Jia Li; Lin Wu
Journal:  Thorac Cancer       Date:  2021-09-09       Impact factor: 3.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.